© 2020 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
Clinical trials showed a high response rate, with almost 85% of participants experiencing tumor shrinkage with this targeted drug.
PARP inhibitor delays disease progression when used after successful chemotherapy.
60% of women treated with the antibody-drug conjugate experienced complete or partial tumor shrinkage.
Novel antibody-drug conjugate shrank tumors in more than 40% of people previously treated with immunotherapy.
New targeted therapy improves survival in people with metastatic HER2-positive breast cancer.
To take advantage of these new therapies, people must first learn whether their cancer harbors targetable mutations.
New site-agnostic therapies highlight the importance of genetic testing.
Emily Garnett, 34, is a mom, wife and lawyer turned writer and podcast host living with metastatic breast cancer in the New York City area.
First targeted therapy may prolong survival of men with advanced prostate cancer.
Imbruvica, Calquence and Venclexta demonstrate good results in combination regimens.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
